PFE Pfizer Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
18:22
Jul 09
Jul 09
Pfizer fails to overturn a cancer drug patent cancellation, according to a report from the news wire.
04:19
Jul 08
Jul 08
JP Morgan cuts its price target on Pfizer shares to 28 dollars from 30 dollars.
00:01
Jul 08
Jul 08
No growth, high dividend but avoid.
Pfizer has earnings growth problems and the Seagen acquisition hasn't worked out; despite a safe 7% dividend, Cramer cannot identify where growth will come from, making him unable to be positive on the stock.
MED
17:38
Jul 03
Jul 03
Sarcastic commentary on activist engagement at PFE; no explicit directional stance or catalyst.
LOW
17:28
Jul 03
Jul 03
Watch PFE: author criticizes Pfizer's pipeline and says the company should be put out of its misery, but does not state a personal short position or actionable short trade.
MED
13:43
Jun 30
Jun 30
US House committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their drug trials in China.
13:43
Jun 30
Jun 30
US House Committee sends letters to Pfizer, Eli Lilly, and Bristol Myers Squibb probing their China drug trials.
13:01
Jun 30
Jun 30
Pfizer confirms receiving a letter from the US House Committee probing its China drug trials.
04:59
Jun 29
Jun 29
Pfizer's GLP-1 medication has advanced past initial review for China's medical insurance drug list, according to an official.
01:45
Jun 24
Jun 24
Pfizer's CFO departing to Nike; corporate personnel news, no trade thesis.
LOW
01:24
Jun 23
Jun 23
Author defends Pfizer and related biotech names against activist Starboard but uses defensive language ("we need them", "careful") without stating a personal position or forward call.
20:42
Jun 22
Jun 22
Pfizer announced that its experimental drug sigvotatug vedotin failed to improve survival in patients with advanced lung cancer.
20:38
Jun 22
Jun 22
Pfizer's phase 3 trial of sigvotatug vedotin in previously treated metastatic NSCLC missed its overall survival goal versus docetaxel, though the drug maintained a manageable safety profile.
12:31
Jun 18
Jun 18
Pfizer's Chief Financial Officer Dave Denton will step down from his role in August, and the company has begun a search for his replacement.
12:01
Jun 18
Jun 18
Premarket movers show mixed Mag 7 performance with Accenture tumbling on weak forecast, Albemarle rising on Citi upgrade, and Rumble jumping on business unit restructuring plans.
12:00
Jun 18
Jun 18
US pre-market movers show Intel up 9% on Trump's comment about Apple working with Intel for chip design, while Accenture drops 14% on disappointing revenue and profit outlook.
11:57
Jun 18
Jun 18
Accenture, Albemarle, Apple, Pfizer, and SpaceX are among the stocks highlighted as drawing Wall Street's attention ahead of the market open.
10:46
Jun 18
Jun 18
Pfizer announces CFO Dave Denton will step down on August 15 with Cecile Guegan named interim CFO effective August 16.
10:46
Jun 18
Jun 18
Pfizer's chief financial officer Denton will step down from his role at the pharmaceutical company.
03:47
Jun 17
Jun 17
The author notes that most large pharma companies have seen minimal M&A activity over the last 24 months while Eli Lilly remains aggressive, providing a factual observation rather than a trade call.
LOW
03:40
Jun 17
Jun 17
The author presents a factual analysis of M&A activity in the biotech sector since Covid, noting that many large pharma companies have not yet engaged in significant deals, but does not express a personal position or forward-looking trade call.
LOW
11:19
Jun 10
Jun 10
Pfizer's CEO states the company is assessing the timing and scope of some intended investments in Germany according to a letter.
11:19
Jun 10
Jun 10
Pfizer CEO states that the investment climate in Germany is becoming increasingly difficult for long-term commitments according to a letter.
11:19
Jun 10
Jun 10
Pfizer's CEO claims in a letter to Chancellor Merz that Germany's current policies are changing prices and the market environment for the pharma industry.
18:30
Jun 06
Jun 06
Pfizer releases new data on an experimental weight-loss shot and outlines a strategy to compete in the obesity drug market dominated by first-mover advantages.
13:41
Jun 06
Jun 06
Pfizer plans to initiate ten Phase 3 studies of its obesity drug candidate berobenatide in 2026 as part of over twenty total obesity trials.
13:41
Jun 06
Jun 06
Pfizer reports that its experimental drug berobenatide achieved nearly 16 percent weight loss at 32 weeks in the VESPER-1 trial at a 2.4 mg weekly dose.
13:41
Jun 06
Jun 06
Pfizer reports robust Phase 2b efficacy and favorable tolerability data supporting monthly dosing for its GLP-1 RA berobenatide.
13:03
Jun 06
Jun 06
Pfizer outlines its strategy to enter the obesity drug market and compete for industry leadership despite having no current products in that category.
12:26
Jun 05
Jun 05
Author provides a detailed valuation analysis for ABVX with a 105% premium price target of ~$218, implying a bullish acquisition thesis based on comps and peak sales multiples.
LOW
About PFE Analyst Coverage
Buzzberg tracks PFE (Pfizer Inc.) across 17 sources. 9 bullish vs 0 bearish calls from 25 analysts. Sentiment: predominantly bullish (16%). 58 total trade ideas tracked. Latest voices: LiveSquawk, FirstSquawk, Jim Cramer.